Bernard Roubert

1.3k total citations
24 papers, 1.0k citations indexed

About

Bernard Roubert is a scholar working on Hematology, Genetics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Bernard Roubert has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 21 papers in Genetics and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Bernard Roubert's work include Hemoglobinopathies and Related Disorders (21 papers), Iron Metabolism and Disorders (13 papers) and Acute Myeloid Leukemia Research (8 papers). Bernard Roubert is often cited by papers focused on Hemoglobinopathies and Related Disorders (21 papers), Iron Metabolism and Disorders (13 papers) and Acute Myeloid Leukemia Research (8 papers). Bernard Roubert collaborates with scholars based in Switzerland, Italy and United States. Bernard Roubert's co-authors include Dany Habr, Gabor Domokos, John B. Porter, Alì Taher, Amal El‐Beshlawy, Mohsen Saleh Elalfy, Maria Domenica Cappellini, Vip Viprakasit, Chi Kong Li and Antonis Kattamis and has published in prestigious journals such as Blood, Nephrology Dialysis Transplantation and Haematologica.

In The Last Decade

Bernard Roubert

24 papers receiving 998 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard Roubert Switzerland	11	933	914	164	104	41	24	1.0k
Gabor Domokos Switzerland	11	854 0.9×	849 0.9×	158 1.0×	106 1.0×	30 0.7×	33	951
Maria Rosaria Fasulo Italy	9	429 0.5×	387 0.4×	50 0.3×	22 0.2×	43 1.0×	16	545
Lee Lee Chan Malaysia	9	256 0.3×	243 0.3×	79 0.5×	40 0.4×	16 0.4×	22	340
Mónica Martín‐Salces Spain	13	529 0.6×	158 0.2×	42 0.3×	29 0.3×	59 1.4×	28	610
Fuad El Rassi United States	11	296 0.3×	255 0.3×	47 0.3×	19 0.2×	38 0.9×	45	387
Grant McQuaker United Kingdom	11	319 0.3×	144 0.2×	28 0.2×	50 0.5×	68 1.7×	21	548
Áurea Cervera Spain	11	152 0.2×	130 0.1×	49 0.3×	42 0.4×	69 1.7×	40	379
Angela Melpignano Italy	9	289 0.3×	253 0.3×	57 0.3×	10 0.1×	45 1.1×	24	358
Antonia Hatziliami Greece	9	534 0.6×	636 0.7×	66 0.4×	22 0.2×	24 0.6×	10	742
Shahla Ansari Iran	12	183 0.2×	150 0.2×	80 0.5×	10 0.1×	38 0.9×	46	371

Countries citing papers authored by Bernard Roubert

Since Specialization

Citations

This map shows the geographic impact of Bernard Roubert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Roubert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Roubert more than expected).

Fields of papers citing papers by Bernard Roubert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Roubert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Roubert. The network helps show where Bernard Roubert may publish in the future.

Co-authorship network of co-authors of Bernard Roubert

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Roubert. A scholar is included among the top collaborators of Bernard Roubert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Roubert. Bernard Roubert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Macdougall, Iain C., Andreas Böck, Fernando Carrera, et al.. (2013). The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation. 29(4). 843–850. 32 indexed citations

Finelli, Carlo, Matteo Giovanni Della Porta, Pierre Fenaux, et al.. (2012). Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 97(9). 1364–1371. 124 indexed citations

Pennell, Dudley J., John B. Porter, Maria Domenica Cappellini, et al.. (2012). Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with -thalassemia major. Haematologica. 97(6). 842–848. 107 indexed citations

Porter, John B., Kai‐Hsin Lin, Photis Beris, et al.. (2011). Response of iron overload to deferasirox in rare transfusion‐dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. European Journal Of Haematology. 87(4). 338–348. 24 indexed citations

Taher, Alì, Mohsen Saleh Elalfy, Shahina Daar, et al.. (2011). Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β‐thalassaemia: results from the ESCALATOR study. European Journal Of Haematology. 87(4). 349–354. 9 indexed citations

Taher, Alì, Mohsen Saleh Elalfy, Shahina Daar, et al.. (2011). Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7‐yr follow‐up from the ESCALATOR study in patients with β‐thalassaemia. European Journal Of Haematology. 87(4). 355–365. 28 indexed citations

Gattermann, Norbert, Carlo Finelli, Matteo Giovanni Della Porta, et al.. (2011). 340 Improvement in haematologic parameters in patients with MDS treated with the iron chelator deferasirox (Exjade®): An EPIC study post-hoc analysis. Leukemia Research. 35. S136–S137. 1 indexed citations

Viprakasit, Vip, Hishamshah Mohd Ibrahim, Sy Ha, et al.. (2011). Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology. 93(3). 319–328. 10 indexed citations

Cappellini, Mohsen Saleh Elalfy, Amal El‐Beshlawy, et al.. (2010). EFFICACY OF DEFERASIROX IN PATIENTS WITH THALASSAEMIA MAJOR IS NOT AFFECTED BY A HISTORY OF HEPATITIS B OR C. UCL Discovery (University College London). 1 indexed citations

10.

Pennell, Dudley J., John B. Porter, Maria Domenica Cappellini, et al.. (2010). CONTINUED IMPROVEMENT IN CARDIAC T2*WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS. UCL Discovery (University College London). 2 indexed citations

11.

Gattermann, Norbert, Carlo Finelli, Matteo Giovanni Della Porta, et al.. (2010). Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leukemia Research. 34(9). 1143–1150. 138 indexed citations

12.

Pennell, Dudley J., John B. Porter, Maria Domenica Cappellini, et al.. (2010). Continued improvement in myocardial T2* over two years of deferasirox therapy in -thalassemia major patients with cardiac iron overload. Haematologica. 96(1). 48–54. 61 indexed citations

13.

Gattermann, Norbert, Carlo Finelli, Matteo Giovanni Della Porta, et al.. (2010). Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria. Blood. 116(21). 2912–2912. 7 indexed citations

14.

Lee, Jong Wook, Sung‐Soo Yoon, Arnold Ganser, et al.. (2010). Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 116(14). 2448–2454. 56 indexed citations

15.

Pennell, Dudley J., John B. Porter, Maria Domenica Cappellini, et al.. (2010). Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years. Blood. 116(21). 4276–4276. 6 indexed citations

16.

Cappellini, Maria Domenica, John B. Porter, Amal El‐Beshlawy, et al.. (2009). Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 95(4). 557–566. 233 indexed citations

17.

Pennell, Dudley J., John B. Porter, Maria Domenica Cappellini, et al.. (2009). Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 115(12). 2364–2371. 158 indexed citations

18.

Porter, John B., Donald K. Bowden, Jacques Troncy, et al.. (2009). Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.. Blood. 114(22). 2486–2486. 6 indexed citations

19.

Gattermann, Norbert, Mathias Schmid, Agnès Guerci‐Bresler, et al.. (2009). Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.. Blood. 114(22). 3803–3803. 4 indexed citations

20.

Gattermann, Norbert, Mathias Schmid, A. Guerci-Bresler, et al.. (2009). P140 Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in ironoverloaded patients with myelodysplastic syndromes (MDS). Leukemia Research. 33. S140–S141. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact